Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 2 Study of Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Next Previous
Trial Profile

A Multicenter Phase 2 Study of Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 10 Feb 2025 Status changed from suspended to recruiting.
  • 07 Dec 2024 According to an abstract published at 66th American Society of Hematology Annual Meeting and Exposition, trial is currently open for enrollment at UCSF and is expected to open at multiple centers through the University of California Hematologic Malignancies Consortium
  • 07 Dec 2024 Study design discussed in an abstract published at 66th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top